Test Report – Insights Into Breast Cancer
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease
Southwest March 1, 2021

Meeting Chair
Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA
Test Chair 2
Test Name 2
Test Location 2
Central April 7, 2021
Meeting Chair
Debu Tripathy, MD
MD Anderson Cancer Center, Houston, TX
Region 3 test test date
Faculty Members
Faculty member content goes here.
More Info
- Virtual Series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Info
- Virtual Series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
Report Snapshot
- A virtual, moderated roundtable discussion focusing on the treatment of breast cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained:
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors will comprise 10–15 medical oncologists representative of each region
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.